Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN reduced its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 32.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,619 shares of the specialty pharmaceutical company's stock after selling 9,987 shares during the quarter. Wells Fargo & Company MN owned 0.06% of Collegium Pharmaceutical worth $591,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in COLL. Integrated Quantitative Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $948,000. Foundry Partners LLC boosted its holdings in Collegium Pharmaceutical by 2.4% in the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock worth $463,000 after acquiring an additional 381 shares in the last quarter. Knott David M Jr acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at approximately $943,000. O Shaughnessy Asset Management LLC raised its stake in Collegium Pharmaceutical by 11.7% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 80,710 shares of the specialty pharmaceutical company's stock worth $2,312,000 after acquiring an additional 8,475 shares during the last quarter. Finally, New Age Alpha Advisors LLC purchased a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $40,000.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded up $0.19 during trading on Wednesday, reaching $27.22. The company had a trading volume of 146,136 shares, compared to its average volume of 440,385. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm's 50-day simple moving average is $28.15 and its 200 day simple moving average is $30.21. The firm has a market capitalization of $874.47 million, a PE ratio of 11.66 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. As a group, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $43.60.

Insider Activity

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares of the company's stock, valued at $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,693 shares of company stock worth $2,334,994 over the last three months. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.